What are suitable alternatives to tofacitinib for a patient over 65 years old with rheumatoid arthritis and comorbid hypertension and cardiac disease?

Preferred Alternatives to Tofacitinib in Patients >65 Years with Rheumatoid Arthritis and Cardiovascular Disease

For patients over 65 years old with rheumatoid arthritis and hypertensive cardiac disease, TNF inhibitors, IL-6 inhibitors, abatacept, or rituximab should be used instead of tofacitinib, with TNF inhibitors being the preferred first-line biologic option.

Why Avoid Tofacitinib in This Population

The FDA label explicitly warns that tofacitinib carries increased risks of mortality, major adverse cardiovascular events (MACE), and malignancies in patients ≥50 years with cardiovascular risk factors 1. The ORAL Surveillance trial demonstrated that patients ≥50 years with at least one cardiovascular risk factor had significantly higher rates of:

• All-cause mortality including sudden cardiac death
• MACE (cardiovascular death, myocardial infarction, stroke)
• Thrombotic events (pulmonary embolism, deep venous thrombosis)
• Malignancies particularly lymphomas and lung cancers

2

Post-hoc analyses confirm that patients with pre-existing atherosclerotic cardiovascular disease had nearly double the MACE risk with tofacitinib versus TNF inhibitors (HR 1.98) 3. Your patient's hypertensive cardiac disease places them squarely in this high-risk category.

Recommended Treatment Algorithm

First-Line Biologic Options (in order of preference):

1. TNF Inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab)

   • Strongest safety profile in cardiovascular disease
   • Served as the comparator showing lower risk in ORAL Surveillance 2
   • Should be combined with methotrexate when tolerated for optimal efficacy 4

2. IL-6 Inhibitors (tocilizumab, sarilumab)

   • Effective alternative with favorable cardiovascular safety data
   • Can be used as monotherapy if methotrexate contraindicated 4

3. Abatacept

   • Well-tolerated with good long-term safety
   • Particularly useful if patient has recurrent infections 5

4. Rituximab

   • Effective option, especially in seropositive disease
   • Longer dosing intervals may improve adherence 4

Critical Guideline Recommendations

The 2026 PANLAR guidelines explicitly state that JAK inhibitors are only conditionally recommended in patients ≥65 years with cardiovascular risk factors, and only when biological DMARDs are contraindicated or unavailable 4. This is a conditional (weak) recommendation, meaning it should be avoided when alternatives exist—which they do in your patient's case.

Special Considerations for Your Patient

Hypertensive cardiac disease management:

• Monitor blood pressure closely with any biologic therapy
• TNF inhibitors do not worsen hypertension and may have neutral cardiovascular effects
• IL-6 inhibitors may affect lipid profiles—monitor and manage accordingly

Age-related factors:

• Older patients (≥65 years) have inherently higher infection risk with any immunosuppression 6
• Screen for latent tuberculosis before starting TNF inhibitors
• Ensure vaccinations are up-to-date before initiating therapy 4

If Biologics Fail or Are Contraindicated

Only after documented failure or contraindication to multiple biologics (TNF inhibitors, IL-6 inhibitors, abatacept, rituximab) should JAK inhibitors be reconsidered 4. Even then, the cardiovascular risks must be thoroughly discussed with the patient, and the lowest effective dose should be used with intensive monitoring.

Switching strategy: If switching from failed TNF inhibitor, prefer changing to a different mechanism of action (IL-6 inhibitor, abatacept, or rituximab) rather than cycling to another TNF inhibitor 4.

Common Pitfalls to Avoid

• Do not use tofacitinib simply because it's oral and convenient in this high-risk population—the cardiovascular risks outweigh this benefit
• Do not combine biologics with each other or with JAK inhibitors 4
• Do not use JAK inhibitors as first-line therapy after conventional DMARD failure when biologics are available
• Do not ignore the FDA boxed warnings—they exist specifically for patients like yours 1